FRNM
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's first commercial-stage test, SimpleScreen CRC for colorectal cancer, is under review by the U.S. Food and Drug Administration (FDA).
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q3 | 0.60 | $183M | -$74M |
| 2026 Q2 | -2.59 | $2M | -$40M |
| 2026 Q1 | -2.38 | $4M | -$69M |
| 2025 Q4 | -1.44 | $28M | $30M |